Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fosaprepitant + midazolam
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Intravenous, Buccal, Intranasal, Intramuscular, Oral
01
Overview
Fosaprepitant (MK-0517) is an intravenous antiemetic drug that acts as a prodrug of aprepitant and is used for the prevention of chemotherapy-induced nausea and vomiting (CINV). It works by antagonizing the neurokinin 1 (NK1) receptor. Midazolam is a short-acting benzodiazepine with rapid onset used for sedation, anesthesia induction, seizure control, and anxiety disorders. It enhances the inhibitory action of gamma-aminobutyric acid (GABA) at GABA-A receptors in the central nervous system. The combination may be studied or used in clinical settings where both antiemetic protection and sedation/anxiolysis are required[1][6][8].
- Brand names
- VersedBuccolamBusulfexNayzilamSeizalam
- Other names
- aprepitant prodrugfosaprepitant dimeglumine
02
Targets
TACR1 (Neurokinin‑1 Receptor)BZD site (GABA-A receptor benzodiazepine site)
Beyond the preview
Go deeper on fosaprepitant + midazolam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fosaprepitant + midazolam.